WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today the company will host an AI panel during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The panel, titled "AI in Biopharma: Next Frontier of Medical Innovation," will explore the transf ...

WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, filed for an additional patent, “Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models”, as part of its developing intellectual property portfolio. In October 2023, Tevogen Bio launched its ar ...

Full name for licenses is Anthony Joseph ("A.J.") Cataldo II, PhD, CPA. Retired university accounting professor, CMA, CGMA and author of 10 books and 200+ articles and columns in 50+ different journals and outlets, with experience as CFO, Government Auditor, Public Accountant and Litigation Support Expert Witness in cases involving GM, Ford, and other big cap firms. Years ago, the Securities and Exchange Commission used 3 of my research articles in a fraud case. I have taught at 10 universities including No ...

WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that it will host a compelling panel discussion, "Pioneering the Economics of Health: Balancing Access and Outcomes," during the 43rd Annual J.P. Morgan Healthcare Conference. This panel will bring together global thoug ...

WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that it will host a compelling panel discussion, “Pioneering the Economics of Health: Balancing Access and Outcomes,” during the 43rd Annual J.P. Morgan Healthcare Conference. This panel will bring together global thou ...

WARREN, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced addition responsibilities for key leaders to further expand company capabilities. As part of this leadership evolution: Tapan V Shah, Head of Investor Relations and Corporate Development, will take on added responsibil ...

WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today expresses gratitude to shareholders for their unwavering support and trust in Tevogen Bio and its leadership. The commitment fuels the company’s determination to advance its mission of developing accessible, life-saving therapeu ...

Core Insights - Tevogen Bio reported a significant reduction in net loss, decreasing from $56.8 million in 2023 to $4.3 million in 2024 for the nine months ended September 30 [1] - The company improved its financial position by nearly eliminating its liabilities, reporting $10.5 million as of September 30, 2024, down from $99.9 million as of December 31, 2023 [1][4] - Tevogen's intellectual property and product assets are valued internally at over $10 billion, but these are not reflected on the balance sheet due to US GAAP accounting rules [3][5] - The company has sufficient capital to fund operations for at least the next 33 months, supported by a loan agreement [4] Financial Performance - Tevogen's net loss for the nine months ended September 30, 2024, was $4.3 million, a significant improvement from $56.8 million in the same period of 2023 [1] - The company reported a substantial decrease in liabilities, from $99.9 million at the end of 2023 to $10.5 million by September 30, 2024 [1][4] Intellectual Property and Assets - Tevogen's internally developed intellectual property and product assets are valued at over $10 billion based on discounted cash flow models, but are not included on the balance sheet due to US GAAP restrictions [3][5] - The company holds multiple granted patents and has several pending patents related to its proprietary immunotherapy technologies and artificial intelligence platforms [6] Ownership Structure - Approximately 78% of equity is retained by Tevogen's officers, which is significantly higher than the industry average of 4% [5] - Key employees have also been granted substantial restricted stock units, reflecting a belief in shared ownership of the company's success [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share TVGN The Nasdaq Stock Market LLC Warrants, each exercisable for one share of Common Stock for $11.50 per share TVGNW The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSIT ...

Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm.Tevogen’s success would not be possible without its passionate team united by a common vision.Founders must navigate the need for capital to fuel growth with a vigilant eye on avoiding equity dilution.Our financing options must consider preserving shareholder value and the potential equity dilution of warrant conversion at a strike price ...